PRISTIQ (desvenlafaxine succinate) by Pfizer is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. First approved in 2008.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
PRISTIQ (desvenlafaxine succinate) is an oral extended-release serotonin-norepinephrine reuptake inhibitor (SNRI) approved by the FDA in 2008. It is indicated for major depressive disorder and works by potentiating serotonin and norepinephrine in the central nervous system through inhibition of their reuptake. The exact mechanism remains under investigation, but non-clinical studies confirm its potency and selectivity as an SNRI.
Product faces imminent loss of exclusivity in mid-2027 with low current commercial momentum; brand team is likely in defensive/transition mode with reduced hiring.
unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective SNRI.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of LY03005 vs Pristiq
Switching From SSRI to Desvenlafaxine on Cognitive Functioning
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
Pilot BA Study of New LY03005 vs Pristiq
Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ
Worked on PRISTIQ at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring
Working on PRISTIQ offers limited long-term career development due to imminent LOE and declining commercial activity. Roles are transitional and focused on managing decline rather than driving growth, making this assignment best suited for professionals seeking short-term tactical experience or portfolio consolidation rather than long-term brand building.